Secretion of hydrolytic enzymes by fungal strains, isolated from patients with malignant tumors of head and neck, before, during and after radiotherapy

• Autorzy: Moqbil S. , Kurnatowski P.
• Języki publikacji: EN

Abstrakty

EN

One method of treatment used in cancer therapy is radiotherapy which can injure the oral, pharynx or larynx mucosa and predisposes tissue to the development of fungal infections. The aim of the study paper was the mycological examinations of swabs from the oral cavity and pharynx of patients obtained prior to, in week 3, on the last day of and 3 weeks after radiotherapy, as well as isolation of fungi and identification of the selected parameter of strains pathogenecity, i.e. hydrolytic enzyme release. Forty-three patients with oral cavity, pharynx or larynx carcinoma were examined at four points during a course of radiotherapy: before treatment, in week 3 of treatment, on the last day of treatment and 3 weeks afterwards. The mycological examination was conducted based on a procedure introduced in the Department of Biology and Medical Parasitology, Medical University of Lodz. The activity of the hydrolytic enzymes was evaluated with a bioMerieux API ZYM test kit. More than 2/3 of the patients (68.2%) were found to have a fungal infection in the first examination, 4/5 (80%) in the second, about 3/5 (57.1%) in the third and all (100%) in the last examination. The release of enzymes varied, and on different stages show different inactive enzymes: at the start, α-chymotrypsin and α-mannosidase; at 3 weeks, β-glucuronidase and α-mannosidase; at the end, α-chymotrypsin; at 3 weeks after the end, trypsin, α-chymotrypsin, α-galaktosidase and α-fucosidase. The most frequent species isolated from the patients treated by radiotherapy is Candida albicans and C. glabrata. The latter is characterized by resistance to the majority of antimycotic medications. The isolated strains are characterized by the highest activity of leucine arylamidase, acid phosphatase and naphthol – AS-BI-phosphohydrolase. Considering the enzymes produced, most of the strains can be included to biotypes D₃, C₆ and A.

Słowa kluczowe

EN

secretion; hydrolytic enzyme; fungal strain; isolation; patient; malignant tumour; head; neck; radiotherapy

• Wydawca: -
• Czasopismo: Annals of Parasitology
• Rocznik: 2012
• Tom: 58
• Numer: 1
• Opis fizyczny: p.27-35,fig.,ref.

Twórcy

autor

Moqbil S.

• Department of Biology and Medical Parasitology, Medical University of Lodz, 1 Hallera Square, 90-647 Lodz, Poland

autor

Kurnatowski P.

Bibliografia

• [1] Osuch-Wójcikiewicz E., Bruzgielewicz A. 2010. Complications after radiotherapy of head and neck neoplasms. Otolaryngologia 9: 1-6.
• [2] Murphy B.A., Beaumont J.L., Isitt J., Garden A.S., Gwede C.K., Trotti A.M., Meredith R.F. 2009. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemiotherapy. Journal of Pain and Symptoms Management 38: 522-532.
• [3] Nicolatou-Galitis O., Velegraki A., Sotiropoulou-Lontou A. 2006. Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Support Care Cancer 14: 44-51.
• [4] Bańkowski K., Ciesielski P., Łaszkiewicz J. 2005. Oral cavity complications after head and neck radiotherapy. Poradnik Stomatologiczny 3: 22-26.
• [5] Kozarzewska M., Daszkiewicz M., Olczak-Kowalczyk D., Dembowska-Bagińska B. 2009. The pathological changes of the oral cavity among patients undergoing antineoplasm therapy. Nowa Stomatologia 14: 59-63.
• [6] Meurman J.H., Grönroos L. 2010. Oral and dental health care of oral cancer patients: hyposalivation, caries and infections. Oral Oncology 46: 464-467.
• [7] Sonis S.T. 1998. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncology 34: 39-43.
• [8] Stryjski A., Adamski Z., Borysewicz-Lewicka M. 2002. The risk of yeast-like fungi infections in patients treated by radiotherapy because of head and neck neoplasma. Mikologia Lekarska 9: 125-129.
• [9] Kurnatowska A. 2006 Diagnostic procedures. In: Medical mycology (Eds. A. Kurnatowska, P. Kurnatowski). Promedi, Lodz.
• [10] Kurnatowska A. 2006 Differentiation of selected in traspecies features of fungi and examples of strain biotyping. In: Medical mycology (Eds. A. Kurnatowska, P. Kurnatowski). Promedi, Lodz.
• [11] Pytko-Polończyk J., Krzyściak P., Macura A.B. 2008. Occurrence of Candida albicans biotypes in oral cavity of irradiated patients with nasopharyngeal malignancies. Mikologia Lekarska 15: 197-200.
• [12] Plomer-Niezgoda E., Hryncewicz-Gwóźdź A., Maj J., Baran E., Walów B. 2004. The estimation of the activity of hydrolytic egzoenzymes and of susceptibility of the yeast-like fungi to antifungal agents in patients with CTCL and bullous diseases treated with immunosuppressive therapeutics. Mikologia Lekarska 11: 35-41.
• [13] Łukaszuk C., Krajewska-Kułak E., Niczyporuk W., Theodosopoulou E., Hatzopulu A., Krawczuk-Rybak M., Wojtukiewicz M. 2005. Variations of enzymatic activity and biotypes of the yeast like fungi strains isolated from cancer patients. Annales Academiae Medicae Bialostoc. 50 (supl): 16-19.
• [14] Krajewska-Kułak E., Niczyporuk W., Łukaszuk C., Sobaniec H., Wojtukiewicz M., Krawczuk-Rybak M., Szczurzewski M. 2000. Enzymatic biotype and the susceptibility of Candida albicans strains to antimycotics isolated from oral cavity of patients with cancer disease. Mikologia Lekarska 7: 27-34.
• [15] Brajer B., Batura-Gabryel H. 2007. Enzymatic biotypem of Candida albicans strains isolated from the sputum of lung cancer patients. Mikologia Lekarska 14: 129-132.
• [16] Nowak M. 2010. Contamination of voice prosthesis by potentially pathogenic fungi. PhD Thesis, Medical University, Lodz.